BCAB250117P2500
- 2.04
- +0.04+2.00%
BioAtla Newsroom
BioAtla Analyst Ratings
H.C. Wainwright Downgrades BioAtla(BCAB.US) to Hold Rating
BioAtla Downgraded to Neutral From Buy at H.C. Wainwright
JMP Securities Maintains BioAtla(BCAB.US) With Buy Rating, Maintains Target Price $5
BioAtla: Strong Financials and Promising Clinical Progress Drive Buy Rating
BTIG Maintains BioAtla(BCAB.US) With Buy Rating, Maintains Target Price $13
BioAtla Analyst Ratings
JMP Securities Maintains BioAtla(BCAB.US) With Buy Rating, Maintains Target Price $5
BTIG Initiates BioAtla(BCAB.US) With Buy Rating, Announces Target Price $13
Buy Rating for BioAtla: Promising Pipeline and Strategic Partnerships Fuel Optimistic Outlook
Reni Benjamin's Buy Rating for BioAtla: Strong Pipeline and Financial Health Signal Upside Potential
BioAtla (BCAB) Receives a Buy From J.P. Morgan
JMP Securities Maintains BioAtla(BCAB.US) With Buy Rating, Maintains Target Price $5
Buy Rating for BioAtla: Promising Clinical Assets and Undervaluation Present Investment Opportunity
Buy Rating Affirmed for BioAtla on Strong Clinical Data and Robust Financials
BioAtla Analyst Ratings
Buy Rating for BioAtla: Promising Clinical Data and Strong Financial Position Signal Upside Potential
BioAtla Analyst Ratings
Buy Rating Affirmed for BioAtla on Strong Clinical Data and Strategic Pipeline Progress
Buy Rating Affirmed for BioAtla on Strong Clinical Pipeline and Financial Stability